“A new article outlines a pioneering method of screening a person’s diverse set of antibodies for rapid therapeutic discovery. Antibody proteins are an important part of the human immune system that specificallyRead More…
Keytruda (pembrolizumab) is a drug developed by Merck (or MSD outside of the U.S. and Canada). It has been approved by the U.S. Food and Drug Administration (FDA) and the European Commission for the treatment of aRead More…
At the beginning of this month, European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events (SRE) in adults with advanced malignancies involving bone, basedRead More…
“A team of investigators has found a way to engineer antibodies within an organism, converting autoantibodies that attack ‘self’ tissues into anti-inflammatory antibodies in animal models of two autoimmune diseases.” A teamRead More…
“During the past decade preclinical studies have defined many of the mechanisms used by tumours to hijack the skeleton and promote bone metastasis. This has led to the development and widespread clinicalRead More…
“Emicizumab (trade name Hemlibra, emicizumab–kxwh, ACE910, RO5534262) is a bispecific IgG4 mAb targeting Factors IXa and X. On November 16, 2017, the drug (emicizumab–kxwh) was approved by Food and Drug Administration (FDA) approved to preventRead More…